Morbidity in HIV-1-infected children treated or not treated with highly active antiretroviral therapy (HAART), abidjan, côte d'Ivoire, 2000-04

Journal of Tropical Pediatrics

Volumn 55, Issue 3, 2009, Pages 170-176

  Walenda, Carsten ^a,g   Kouakoussui, Alain ^b   Rouet, François ^c   Wemin, Louise ^b,d   Anaky, Marie France ^b   Msellati, Philippe ^e,f  

^a DEPARTMENT OF NEUROLOGY   (France)

^b Programme Enfant Yopougon/PACCI   (Côte d’Ivoire)

^c CeDReS   (Côte d’Ivoire)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^e UNIVERSITÉ DE MONTPELLIER   (France)

^f CReCSS   (France)

^g NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANEURYSM; ARTICLE; BRONCHITIS; CAUSE OF DEATH; CD4 LYMPHOCYTE PERCENTAGE; CHILD; CONJUNCTIVITIS; CRYPTOCOCCOSIS; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EAR NOSE THROAT DISEASE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALARIA; MALE; MARASMUS; MORBIDITY; MORTALITY; OTITIS; PANCREATITIS; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PSEUDOMONAS INFECTION; SEIZURE; SEPSIS; SKIN INFECTION; SURVIVAL RATE; TUBERCULOSIS; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COTE D'IVOIRE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MORBIDITY; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67049160147     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmn106     Document Type: Article

References (21)

1. UNAIDS WHO. AIDS epidemic update 2007. http://www.unaids.org. Last accessed November 2007.
2. UNAIDS WHO. Report on the global HIV/AIDS epidemic 2006. http://www.unaids.org. Last accessed December 2006.
3. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: A cohort study. Lancet 2000;359:2059-64.
4. Fassinou P, Elenga N, Rouet F, et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'lvoire. AIDS 2004;18:1905-13.
5. Timité-Konan AM, Fassinou P, Adonis Koffy L, N'dja BB. Use of antiretroviral drugs in HIV infected children in a tropical area: A real benefit (in French). Arch Péd 2003;10:831-2.
6. Spira R, Lepage P, Msellati P, et al. Natural history of Human Immunodeficiency Virus type 1 infection in children: A five-year prospective study in Rwanda. Pediatrics 1999;104:e56.
7. Taha T, Graham S, Kumwenda N, et al. Morbidity among Human Immunodeficiency virus-infected and uninfected African children. Pediatrics 2000;106:e77.
8. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004;364:1236-43.
9. François R, Charlotte S, Philippe M et al.; for The Abidjan DITRAME Study Group. Pediatric Viral Human Immunodeficiency Virus Type 1 RNA Levels, Timing Of Infection, And Disease Progression In African HIV-1-Infected Children. Pediatrics 2003;112: E289-97.
10. Lepage P, Van de Perre P, van Vliet G, et al. Clinical and endocrinological manifestations in perinatally HIV-infected children aged five years or more. Am J Dis Child 1991;145:1248-51.
11. Kabore A, Diagbouga S, Manigart O, et al. Absence of clinical progression of HIV infection in children in Burkina Faso (in French). XIIème Congrès International sur le SIDA et les Maladies sexuellement transmissibles en Afrique. Ouagadougou, Burkina Faso, 9-13 décembre 2001.
12. Vetter K, Djomand G, Zadi F, et al. Clinical spectrum of human immunodeficiency virus disease in children in a West African city. Pediatr Infect Dis J 1998; 15:438-42.
13. Nachman S, Gona P, Dankner W, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics 2005;115:488-94.
14. Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA 2006;296: 292-300.
15. Rouet F, Fassinou P, Inwoley A, et al. Long-term survival and immuno-virologic response of African HIV-1-infected children to highly active antiretroviral therapy regimens containing a protease or a nonnucleoside reverse transcriptase inhibitor. AIDS 2006;20:2315-19.
16. Elenga N, Kouakoussui A, Bonard D, et al. Diagnosed Tuberculosis During Follow-up of a Cohort of Human Immunodeficiency Virus-Infected Children in Abidjan, Côte d'lvoire. Pediatr Infect Dis J 2005;24:1-7.
17. World Health Organization, UNAIDS. Provisional WHO/UNAIDS recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Afr Health Sci 2001;1:30-1.
18. Rouet F, Ekouevi DK, Chaix ML, et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a west African resource-limited setting. J Clin Microbiol 2005;43:2709-17.
19. Centers for Disease Control and Prevention. 1994 revised classification systems for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43:1-19.
20. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'lvoire. AIDS 2003;17(Suppl 3): S5 15.
21. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): A double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-71.